The introduction of targeted therapies like the BCR::ABL1 tyrosine kinase inhibitors in Philadelphia-chromosome(Ph)-positive acute lymphoblastic leukemia (ALL), of immune-oncologic therapies like antibodies targeting CD19, CD20 and CD22, as well as chimeric antigen receptor T (CAR-T) cellular therapies in pre-B ALL, is transforming the therapeutic landscape in adult ALL [1–3]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.